cefpodoxime proxetil

Decreased plasma concentrations of cefpodoxime, potentially leading to reduced antibacterial efficacy.

Administer cefpodoxime proxetil at least 2 hours before or after antacids.

Decreased bioavailability and efficacy of cefpodoxime

Administer cefpodoxime proxetil at least 2 hours before or 2 hours after antacids. Consider alternative antibiotics if frequent antacid use is unavoidable.

Decreased bioavailability and efficacy of cefpodoxime

Administer cefpodoxime proxetil at least 2 hours before or 2 hours after H2-receptor antagonists. Consider alternative antibiotics if continuous H2RA therapy is required.

Reduced efficacy of the live typhoid vaccine.

Avoid administering live typhoid vaccine within 24 hours before or after cefpodoxime proxetil. It is generally recommended to complete antibiotic therapy and wait a few days (e.g., 3 days) before administering the live vaccine.

Increased risk of renal impairment

Monitor renal function (serum creatinine, BUN) closely, especially in patients with pre-existing renal impairment or those receiving high doses of either drug. Adjust doses as necessary.

Decreased plasma concentrations of cefpodoxime, potentially leading to reduced antibacterial efficacy.

Avoid co-administration if possible. If prolonged acid suppression is required, consider an alternative antibiotic that is not pH-dependent for absorption. If unavoidable, monitor for reduced efficacy.

Increased INR and bleeding risk

Monitor INR closely, especially at the start and end of cefpodoxime therapy. Adjust warfarin dose as needed.

Increased cefpodoxime plasma levels, potentially leading to increased risk of adverse effects (though often used intentionally to enhance antibiotic effect).

Monitor for increased adverse effects of cefpodoxime. Dose adjustment of cefpodoxime may be necessary if not intended to increase levels.

Decreased bioavailability and efficacy of cefpodoxime

Administer cefpodoxime proxetil at least 2 hours before or 2 hours after PPIs. Consider alternative antibiotics if continuous PPI therapy is required.

Decreased plasma concentrations of cefpodoxime, potentially leading to reduced antibacterial efficacy.

Avoid co-administration if possible. If necessary, administer cefpodoxime proxetil at least 2-4 hours before ranitidine. Consider alternative antibiotics if prolonged acid suppression is required.

Increased INR, increased risk of bleeding.

Monitor INR closely when initiating or discontinuing cefpodoxime proxetil in patients on warfarin. Adjust warfarin dose as needed.

Increased risk of renal dysfunction.

Monitor renal function, especially in patients with pre-existing renal impairment or those receiving high doses of nephrotoxic drugs.